Duopharma Biotech Bhd
KLSE:DPHARMA
Intrinsic Value
Duopharma Biotech Bhd.is an investment holding company, which engages in the manufacturing and distribution of pharmaceutical products. [ Read More ]
The intrinsic value of one DPHARMA stock under the Base Case scenario is 1.79 MYR. Compared to the current market price of 1.22 MYR, Duopharma Biotech Bhd is Undervalued by 32%.
Valuation Backtest
Duopharma Biotech Bhd
Run backtest to discover the historical profit from buying and selling DPHARMA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Balance Sheet Decomposition
Duopharma Biotech Bhd
| Current Assets | 677.1m |
| Cash & Short-Term Investments | 270.5m |
| Receivables | 163.5m |
| Other Current Assets | 243.1m |
| Non-Current Assets | 668.1m |
| Long-Term Investments | 38m |
| PP&E | 582.4m |
| Intangibles | 38.8m |
| Other Non-Current Assets | 8.9m |
| Current Liabilities | 166.7m |
| Accounts Payable | 100.8m |
| Other Current Liabilities | 65.9m |
| Non-Current Liabilities | 491.3m |
| Long-Term Debt | 480.9m |
| Other Non-Current Liabilities | 10.4m |
Earnings Waterfall
Duopharma Biotech Bhd
|
Revenue
|
704.7m
MYR
|
|
Cost of Revenue
|
-436.4m
MYR
|
|
Gross Profit
|
268.3m
MYR
|
|
Operating Expenses
|
-189.6m
MYR
|
|
Operating Income
|
78.7m
MYR
|
|
Other Expenses
|
-26.1m
MYR
|
|
Net Income
|
52.6m
MYR
|
Free Cash Flow Analysis
Duopharma Biotech Bhd
| MYR | |
| Free Cash Flow | MYR |
DPHARMA Profitability Score
Profitability Due Diligence
Duopharma Biotech Bhd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Duopharma Biotech Bhd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
DPHARMA Solvency Score
Solvency Due Diligence
Duopharma Biotech Bhd's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
Duopharma Biotech Bhd's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DPHARMA Price Targets Summary
Duopharma Biotech Bhd
According to Wall Street analysts, the average 1-year price target for DPHARMA is 1.48 MYR with a low forecast of 1.4 MYR and a high forecast of 1.6 MYR.
Shareholder Return
DPHARMA Price
Duopharma Biotech Bhd
| Average Annual Return | 26.98% |
| Standard Deviation of Annual Returns | 67.46% |
| Max Drawdown | -64% |
| Market Capitalization | 1.2B MYR |
| Shares Outstanding | 961 942 016 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Duopharma Biotech Bhd.is an investment holding company, which engages in the manufacturing and distribution of pharmaceutical products. The company is headquartered in Klang, Selangor. The company went IPO on 2002-07-18. The Company, through its subsidiaries is engaged in manufacturing, distribution, importing and exporting of pharmaceutical products and medicines. The firm also engaged in research and development of pharmaceutical products. Its subsidiaries include Duopharma (M) Sendirian Berhad, Duopharma Manufacturing (Bangi) Sdn. Bhd., Duopharma Marketing Sdn. Bhd., Duopharma Consumer Healthcare Sdn. Bhd., Duopharma HAPI Sdn. Bhd., Duopharma Innovation Sdn. Bhd., Unique Pharmacy (Penang) Sdn. Bhd., Sentosa Pharmacy Sdn. Bhd., Duopharma Manufacturing (Glenmarie) Sdn. Bhd., Negeri Pharmacy Sdn. Bhd., Duopharma (Singapore) Pte. Ltd. and DB (Philippines), Inc.
Contact
IPO
Employees
Officers
The intrinsic value of one DPHARMA stock under the Base Case scenario is 1.79 MYR.
Compared to the current market price of 1.22 MYR, Duopharma Biotech Bhd is Undervalued by 32%.
You don't have any saved screeners yet
